Hinge Health Expands into Migraine Care with FDA-Cleared Wearable Device
Event summary
- Hinge Health launched its Migraine Care Program on April 29, 2026, leveraging its FDA-cleared Enso device for rapid drug-free pain relief.
- The program combines AI-powered trigger management and expert-led prevention, targeting the overlap between migraine and musculoskeletal (MSK) pain.
- Over 125 clients covering more than two million people have already adopted the program, with a full rollout scheduled for May 2026.
The big picture
Hinge Health is extending its expertise in MSK care to migraine treatment, capitalizing on the significant overlap between these conditions. The launch aligns with broader industry trends toward digital health solutions that reduce reliance on pharmaceutical interventions. With migraine costing U.S. businesses $78 billion annually, the program's potential to improve productivity and reduce absenteeism positions Hinge Health as a key player in chronic pain management.
What we're watching
- Market Penetration
- Whether Hinge Health can sustain rapid client adoption beyond the initial 125 clients, given the high prevalence of migraine and MSK pain.
- Regulatory Compliance
- The pace at which FDA clearance for the Enso device will drive further innovation in digital health solutions for chronic conditions.
- Cost Efficiency
- How the program's impact on reducing medical and pharmaceutical spend will influence employer adoption and long-term cost savings.
Our editorial coverage:
Related topics